News article rejects lean mass hyper-responder hypothesis, affirms high LDL-C drives atherosclerosis
Updated
Updated · peterattiamd.com · Apr 25
News article rejects lean mass hyper-responder hypothesis, affirms high LDL-C drives atherosclerosis
3 articles · Updated · peterattiamd.com · Apr 25
The article critiques recent studies and the CSF-backed documentary 'The Cholesterol Code,' which claim some lean individuals on ketogenic diets are exempt from LDL-C-driven cardiovascular risk.
It argues that current evidence is insufficient to overturn decades of research showing high LDL-C and apoB levels causally drive atherosclerosis, regardless of metabolic context or phenotype.
The piece urges caution, emphasizing that no robust long-term data support the LMHR hypothesis and that elevated LDL-C should be addressed in all populations to reduce cardiovascular risk.
With top cardiologists saying 'lower is better,' what is the real risk of the documentary's advice?
How can a popular documentary challenge the global scientific consensus on heart disease risk?
After a key study's data was retracted, should keto 'hyper-responders' still ignore their sky-high cholesterol?
Can a healthy metabolism give you a 'free pass' for dangerously high levels of artery-clogging particles?
Is the 'lean mass hyper-responder' a unique metabolic state or a new name for high-risk cholesterol?
Elevated LDL-C Without Plaque Progression: Insights from the 2024 KETO-CTA Study on Metabolically Healthy Keto Responders
Overview
The 2024 KETO-CTA study revealed that lean mass hyper-responders (LMHRs) on long-term ketogenic diets have very high LDL-C levels but do not show accelerated coronary plaque progression. Instead, their baseline plaque burden predicts future progression, highlighting the importance of arterial health over LDL-C alone. LMHRs display a unique metabolic profile with low BMI, high HDL-C, low triglycerides, and low inflammation, challenging the traditional lipid hypothesis that links high LDL-C directly to atherosclerosis. However, methodological gaps, including the lack of a proper control group, have led experts to caution against dismissing LDL-C as a risk factor. These findings suggest personalized risk assessment using advanced imaging is crucial, and future long-term studies are needed to clarify cardiovascular risk in this group.